Trial Profile
The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs LEO 27847 (Primary)
- Indications Hyperparathyroidism; Kidney disorders
- Focus Pharmacokinetics
- Sponsors LEO Pharma
- 05 Apr 2016 New trial record